Northstar Advisory Group LLC Has $2.39 Million Position in Stryker Co. (NYSE:SYK)

Northstar Advisory Group LLC boosted its holdings in shares of Stryker Co. (NYSE:SYK) by 3.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,623 shares of the medical technology company’s stock after buying an additional 241 shares during the period. Stryker makes up about 1.2% of Northstar Advisory Group LLC’s portfolio, making the stock its 29th largest position. Northstar Advisory Group LLC’s holdings in Stryker were worth $2,385,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in SYK. Sunflower Bank N.A. lifted its position in Stryker by 5.9% in the 4th quarter. Sunflower Bank N.A. now owns 665 shares of the medical technology company’s stock valued at $239,000 after acquiring an additional 37 shares in the last quarter. Eastern Bank lifted its holdings in shares of Stryker by 2.2% in the fourth quarter. Eastern Bank now owns 3,813 shares of the medical technology company’s stock valued at $1,373,000 after purchasing an additional 83 shares in the last quarter. Fulcrum Capital LLC boosted its position in shares of Stryker by 26.4% during the fourth quarter. Fulcrum Capital LLC now owns 1,915 shares of the medical technology company’s stock valued at $689,000 after buying an additional 400 shares during the last quarter. Harbour Capital Advisors LLC grew its holdings in Stryker by 179.2% during the fourth quarter. Harbour Capital Advisors LLC now owns 1,703 shares of the medical technology company’s stock worth $616,000 after buying an additional 1,093 shares in the last quarter. Finally, Forza Wealth Management LLC grew its stake in shares of Stryker by 6.1% in the 4th quarter. Forza Wealth Management LLC now owns 885 shares of the medical technology company’s stock worth $319,000 after acquiring an additional 51 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

NYSE:SYK traded down $4.70 during trading hours on Monday, hitting $360.96. The stock had a trading volume of 1,400,602 shares, compared to its average volume of 1,302,026. The firm has a market capitalization of $137.60 billion, a price-to-earnings ratio of 38.69, a P/E/G ratio of 2.82 and a beta of 0.95. Stryker Co. has a one year low of $307.23 and a one year high of $398.20. The company has a 50 day simple moving average of $375.40 and a two-hundred day simple moving average of $357.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same period in the prior year, the company earned $2.46 EPS. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. Research analysts forecast that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.93%. This is a boost from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio (DPR) is 36.01%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on SYK. Barclays upped their target price on Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Evercore ISI raised their target price on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Needham & Company LLC reiterated a “buy” rating and set a $442.00 target price on shares of Stryker in a research note on Tuesday, January 7th. JMP Securities restated a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Finally, Canaccord Genuity Group lifted their price target on shares of Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average price target of $405.80.

Insider Buying and Selling

In other news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.90% of the stock is owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.